REGENERON AND SANOFI ANNOUNCE APPROVAL OF DUPIXENT® (DUPILUMAB) TO TREAT ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN THE EUROPEAN UNION
-- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has granted marketing authorization for DUPIXENT ® (dupilumab), for use in adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. Atopic dermatitis, a form of eczema, is a chronic inflammatory disease with symptoms often appearing as a rash on the skin. Moderate-to-severe atopic dermatitis is characterized by rashes often covering much of the body, and can include intense, persistent itching and skin dryness, cracking, redness, crusting, and oozing. Itch is one of the most burdensome symptoms for patients and can be debilitating. In addition, people with moderate-to-severe atopic dermatitis experience impaired quality of life, including disrupted sleep, and increased anxiety and depression symptoms along with their disease. "People with moderate-to-severe atopic dermatitis can experience unbearable symptoms that m